

Resource Summary Report

Generated by [RRID](#) on Aug 3, 2026

AC29

RRID:CVCL_4407

Type: Cell Line

Proper Citation

RRID:CVCL_4407

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_4407

Proper Citation: RRID:CVCL_4407

Description: Cell line AC29 is a Cancer cell line with a species of origin *Mus musculus* (Mouse)

Sex: Female

Disease: Mouse mesothelioma

Defining Citation: [PMID:1459729](#), [PMID:22581112](#), [PMID:28577549](#), [PMID:32944078](#)

Comments: Karyotypic information: Hyper-triploid (PubMed=32944078)., Problematic cell line: Partially contaminated. The stock formerly distributed by CBA under the catalog number CBA-0152 was a mixture of at least two different cell lines from different mouse strains..

Category: Cancer cell line

Organism: *Mus musculus* (Mouse)

Name: AC29

Cross References: CBA:CBA-0152, CBA:CBA-1664, ECACC:10092308, ECACC:21102109, Wikidata:Q54607945

ID: CVCL_4407

Record Creation Time: 20220427T215126+0000

Record Last Update: 20260802T005727+0000

Ratings and Alerts

No rating or validation information has been found for AC29.

Warning: Problematic cell line: Partially contaminated. The stock formerly distributed by CBA under the catalog number CBA-0152 was a mixture of at least two different cell lines from different mouse strains.

Karyotypic information: Hyper-triploid (PubMed=32944078)., Problematic cell line: Partially contaminated. The stock formerly distributed by CBA under the catalog number CBA-0152 was a mixture of at least two different cell lines from different mouse strains.. **Warning:** Discontinued: CBA; CBA-0152

Karyotypic information: Hyper-triploid (PubMed=32944078)., Problematic cell line: Partially contaminated. The stock formerly distributed by CBA under the catalog number CBA-0152 was a mixture of at least two different cell lines from different mouse strains..

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

van Gulijk M, et al. (2023) Combination of PD-1/PD-L1 checkpoint inhibition and dendritic cell therapy in mice models and in patients with mesothelioma. International journal of cancer, 152(7), 1438.

Dammeijer F, et al. (2020) The PD-1/PD-L1-Checkpoint Restrains T??cell Immunity in Tumor-Draining Lymph Nodes. Cancer cell, 38(5), 685.